Back to catalogue
№ 118 32 filings · 2021-09-16 → 2026-09-28

CHECKIT PLC

CKT
Technology Share price 15.25p Market cap £16m Overall fit 420 /1000

Strong operating-leverage profile and a fair-to-slightly-cheap valuation, but AI-beneficiary angle is weak (AI is used internally to speed up engineering, not a revenue driver) and downside protection is limited by sub-scale and £2.9m cash. Partial fit for the strategy.

Fair value range 22p–32p Mid case · £29m
Absolute upside +76.1% vs current market cap
Conviction 3/5 confidence in fair call
Supports the call
  • Clean, audited disclosure and clear KPI reporting
  • H1 FY27 operating-leverage inflection is well-evidenced
  • Failed FSP provides externally-validated ceiling on strategic value
Limits the call
  • Fair value highly sensitive to EV/ARR multiple assumed
  • Sub-scale (£12.8m ARR, £2.9m cash) leaves little room for execution error
Methodology

EV/ARR multiple cross-checked with forward EV/EBITDA

In one line · bull case

Post-restructuring, high-operating-leverage vertical SaaS at fair valuation with clear inflection to profitability and a sticky medical-monitoring franchise.

In one line · biggest risk

Sub-scale £12.8m ARR business with £2.9m cash and a failed formal sale process — thin margin for execution error and limited market validation of strategic value.

Drivers
AI beneficiary 35 /100
AI mentioned as an engineering productivity tool and analytics module (Asset Intelligence); no material AI-driven revenue line — a mild indirect beneficiary at best.
Operating leverage 75 /100
97% recurring, 69% gross margin, largely fixed cost base; H1 FY27 delivered £1.2m EBITDA swing on £0.2m revenue growth.
Earnings vs expectations 60 /100
Profit/cost metrics have modestly beaten; top-line ARR bookings have repeatedly been characterised as impacted by lengthening sales cycles.
Growth momentum 45 /100
Continuing ARR +5% at constant currency; total revenue flat-to-declining; not accelerating.
Moat 45 /100
Sticky embedded workflows in regulated environments (94% GRR) but sub-scale and facing hardware-led and enterprise-QMS competitors.
Earnings quality 65 /100
Adjusted EBITDA is close to reported; regular non-recurring items (restructuring, transaction costs) but disclosed transparently; unqualified audit.
Management quality 50 /100
Delivered structural cost reset ahead of plan but repeated aborted M&A (Crimson Tide, FSP) and modest top-line execution are drags.
Cyclicality 30 /100
Regulated Medical vertical (71% of revenue) is defensive; hospitality/retail exposure adds modest cyclicality.
Leverage 10 /100
£2.9m net cash, no financial debt; only balance-sheet risk is limited liquidity buffer.
Value-trap signals · 5
  • Total revenue declining across FY24-FY26 (£14.1m→£13.7m→£12.1m continuing)
  • Formal Sale Process 2026 attracted no recommendable offers
  • Customer concentration (one customer 13% of revenue)
  • Repeated aborted M&A (Crimson Tide 2025, six unsolicited approaches FY26)
  • ARR growth headline repeatedly excludes 'one large US customer' contraction

CHECKIT PLC (CKT) — Investment Research Note

Executive summary

Checkit is a UK-listed vertical SaaS/IoT platform combining medical-grade sensor monitoring with digital workflow software, sold predominantly into US plasma-collection centres, NHS trusts, private hospitals and premium multi-site retail/hospitality operators. After three years of losses, cost restructuring (£4m annualised savings in FY26, headcount 165→117) and a strategic focus on recurring revenue (97% of H1 FY27) drove the business to adjusted EBITDA break-even in FY26 and £0.3m adj. EBITDA in H1 FY27 despite only 3–4% revenue growth — a textbook operating-leverage inflection 2026-09-28 H1 FY27, 2026-04-21 FY26. The single most valuation-relevant point today: a Formal Sale Process launched March 2026 was terminated in September 2026 with no offers at values the Board could recommend, meaning strategic buyers priced the equity well below current expectations even with cost-normalisation synergies stripped in.

Fair value estimate

Fair value range: 22p – 32p per share (implied market cap £24m – £35m)

Methodology: EV/ARR multiple triangulated with EV/forward-EBITDA sense-check.

  • Continuing ARR at 31 July 2026: £12.8m 2026-09-28 H1 FY27
  • Balance-sheet cash: £2.9m; no financial debt
  • Range applies 1.7x – 2.5x EV/ARR for a sub-scale, EBITDA-breakeven-but-improving vertical SaaS on AIM with 94% gross retention, 97% recurring mix, and demonstrable operating leverage — but sub-£15m ARR and no bidder found in a formal process
  • Mid-point EV £25m + £2.9m cash → **£28m market cap → 26p per share (+15% vs 22.5p)**

Sense-check: at ~£1.5m FY28E adj. EBITDA (adding 10% ARR growth × ~70% contribution margin to the £0.6m H1 FY27 run-rate), 15–20x EV/EBITDA gives £22–30m EV — consistent.

Comparison to £24.3m current market cap: the shares sit in the lower half of the fair-value range. View: fair, with modest upside.

Sector context

Classification confirmed: Technology / vertical SaaS + industrial IoT hybrid. Quality vs sector peers is below average on scale (sub-£15m ARR vs UK SaaS peers £50m+), in line on gross margin (69%), above average on customer stickiness (94% GRR, 102% NRR), and below average on balance-sheet resilience (only £2.9m cash vs £11m two years ago). Nearest listed proxies: Cerillion (billing SaaS), dotDigital (marketing SaaS), Craneware (US healthcare SaaS) — all substantially larger and higher-multiple. Closest direct comparable, Crimson Tide (mpro5 workflow SaaS), was the target of Checkit's own aborted 2025 merger and demonstrates how thin the AIM workflow-SaaS peer set is.

Investment thesis

  • Clear inflection to profitability with high operating leverage. H1 FY27 adj. EBITDA swung by £1.2m to a £0.3m profit on only £0.2m of revenue growth, evidencing the £4m cost-programme benefit landing on a 97%-recurring, 69%-gross-margin base 2026-09-28 H1 FY27. Each incremental £1m of ARR should convert at ~70% to EBITDA against a now-stable fixed cost base.
  • Sticky, regulated Medical franchise (71% of H1 FY27 revenue) with defensible integration. Positions with UK NHS, US plasma-collection networks (e.g. Octapharma expansion signed June 2024), private hospitals and biotech; Board is unifying the platform onto one modern cloud codebase (Next-Gen Medical Monitoring) enabling workflow cross-sell into a customer base that previously only had sensing 2026-09-28 H1 FY27, 2025-08-26 H1 FY26.
  • Downside supported by strategic optionality and net cash. Even after a failed FSP, the process "provided valuable external validation of the strength of technology, customer proposition and position in regulated environments" 2026-09-28. £2.9m net cash, no debt, positive H2 FY26 and H1 FY27 operating cash flow (£0.7m in H1 FY27), and £5.8m of contracted deferred revenue provide a working-capital cushion.

Key risks

  • Sub-scale balance sheet. £2.9m cash against £0.7m H1 capex and ongoing platform-unification investment leaves limited margin for error; a single bad quarter could force a placing at a depressed price 2026-09-28 H1 FY27.
  • ARR growth remains anaemic and gross retention below target. Constant-currency ARR growth 5%, GRR 94% vs stated 95%+ target, NRR 102% vs 105–110% target; the two-year value-creation framework is contingent on tighter execution that management admits is required, not delivered 2026-09-28. Legacy product retirement removed £1.6m ARR — an admission that not all revenue was defensible.
  • Failed FSP and repeated aborted M&A are a governance/valuation signal. Six unsolicited approaches in FY26 and a formal process yielded no recommendable offer; the Crimson Tide merger was abandoned; the earlier Crimson Tide MSA was disrupted by an Ideagen approach 2026-04-21 FY26, 2025-04-24 FY25, 2025-02-11 Merger. Cumulatively suggests trade buyers see less strategic value than the Board does.

Operating leverage

Operating leverage is the single most attractive attribute of this stock. The FY26 cost programme reset the fixed cost base to c.£8–9m of operating expenses supporting 97% recurring revenue at 69% gross margin. The H1 comparison is the proof point: revenue +£0.2m, gross profit +£0.3m, opex −£0.9m, adj. EBITDA +£1.2m 2026-09-28. On a forward basis, assuming opex holds and gross margin trends toward 70%+, each incremental £1m of ARR should contribute ~£0.7m to adjusted EBITDA. A 15% ARR beat vs plan (£1.9m of extra recurring revenue) would plausibly triple EBITDA to £1.5m+. Inflection points are visible: (i) the £0.7m annualised cost saving from legacy product retirement, (ii) planned Q4 FY27 launch of Next-Gen Medical Monitoring enabling workflow cross-sell into medical customers "for the first time" 2026-04-21 FY26, and (iii) platform unification reducing duplicated R&D/infrastructure. Cited leverage is real, though the base is small enough that a £1–2m EBITDA outcome is still a modest absolute number.

Value-trap signals

  • Total revenue declining (£14.1m → £13.7m → £12.1m continuing) even before discontinued-operation reclassification
  • Formal Sale Process failed to attract recommendable offers — the clearest market-validated signal that strategic buyers see limited upside
  • Customer concentration: one customer 13% of revenue 2026-04-21 FY26
  • Repeated aborted M&A (Crimson Tide 2025, six unsolicited approaches during FY26)
  • ARR growth reliant on excluding a "single large US customer" contraction each year — a recurring "underlying" adjustment
  • Sub-scale and dependent on continued expense discipline against thin £2.9m cash

Earnings vs. expectations

Where analyst consensus is referenced: FY24 delivered in line ("in line with the Board's and market expectations") 2024-04-25; H1 FY25 delivered "in line" with LBITDA better than expected 2024-09-12; FY26 delivered EBITDA break-even ahead of expectations of a £0.7m loss and cash ahead of the £15.2m consensus 2026-02-19 trading update, 2026-04-21 FY26; H1 FY27 delivered EBITDA and cash ahead of prior-year comparables consistent with guidance 2026-09-28. The pattern is broadly meet-to-beat on cost/profit, meet-to-slightly-miss on top-line — bookings and ARR growth has repeatedly been characterised as "impacted by lengthening sales cycles" or "one large US customer" contractions. Net: profit trajectory has beaten, revenue growth has disappointed.

Conviction

Conviction: 3 (moderate). Anchors: (i) financials are cleanly disclosed and audit-unqualified, (ii) the operating-leverage math is well-evidenced by the H1 FY27 print, (iii) the FSP outcome provides an independent, market-tested cap on strategic value. Limiters: (i) fair value is highly sensitive to which EV/ARR multiple is chosen — a 1.5x vs 2.5x range spans 30% up or 15% down from spot, (ii) the business is sub-scale enough that a modest execution stumble could invalidate the profitability thesis quickly.

Filings consulted · 36

Every document the LLM read for this note. Click any row to open the source.

  1. 2026-09-28Interim Results2026-09-28_9792925_interim-results.md0.90
  2. 2026-05-22Result OF Agm2026-05-22_9583063_result-of-agm.md0.30
  3. 2026-04-27Posting OF Annual Report And Notice OF Agm2026-04-27_9539692_posting-of-annual-report-and-notice-of-agm.md0.95
  4. 2026-04-21Final Results2026-04-21_9529267_final-results.md1.00
  5. 2026-02-19Fy26 Trading Update2026-02-19_9437269_fy26-trading-update.md0.72
  6. 2025-08-26Interim Results2025-08-26_9071340_interim-results.md0.58
  7. 2025-06-05Result OF Agm2025-06-05_8915578_result-of-agm.md0.20
  8. 2025-05-29Posting OF Annual Report And Notice OF Agm2025-05-29_8901404_posting-of-annual-report-and-notice-of-agm.md0.62
  9. 2025-04-24Final Results2025-04-24_8843078_final-results.md0.65
  10. 2025-04-17Notice OF Results And Investor Presentation2025-04-17_8835708_notice-of-results-and-investor-presentation.md0.46
  11. 2025-04-08Strategic Update2025-04-08_8818389_strategic-update.md0.62
  12. 2025-03-11Offer Update2025-03-11_8772261_offer-update.md0.52
  13. 2025-02-11Recommended All Share Merger With Crimson Tide2025-02-11_8730280_recommended-all-share-merger-with-crimson-tide.md0.49
  14. 2024-09-12Interim Results2024-09-12_8412411_interim-results.md0.41
  15. 2024-09-04Notice OF Results And Investor Presentation2024-09-04_8398123_notice-of-results-and-investor-presentation.md0.32
  16. 2024-04-25Final Results2024-04-25_8155604_final-results.md0.45
  17. 2024-04-17Notice OF Results And Investor Presentation2024-04-17_8143081_notice-of-results-and-investor-presentation.md0.32
  18. 2024-02-15Trading Update2024-02-15_8038754_trading-update.md0.38
  19. 2024-02-05Investor Presentation2024-02-05_8020754_investor-presentation.md0.32
  20. 2023-09-14Interim Results2023-09-14_7754321_interim-results.md0.23
  21. 2023-08-24Investor Presentation2023-08-24_7714170_investor-presentation.md0.17
  22. 2023-08-10Trading Update Notice OF Results Amp Contract2023-08-10_7687166_trading-update-notice-of-results-amp-contract.md0.21
  23. 2023-06-08Result OF Agm2023-06-08_7566935_result-of-agm.md0.07
  24. 2023-05-15Posting OF Annual Report And Notice OF Agm2023-05-15_7527477_posting-of-annual-report-and-notice-of-agm.md0.24
  25. 2023-04-13Notice OF Results And Investor Presentation2023-04-13_7489387_notice-of-results-and-investor-presentation.md0.17
  26. 2023-02-16Trading Update And Notice OF Results2023-02-16_7482095_trading-update-and-notice-of-results.md0.21
  27. 2023-01-05Contract Wins And Investor Presentation2023-01-05_7310203_contract-wins-and-investor-presentation.md0.17
  28. 2022-09-15Interim Results2022-09-15_7316231_interim-results.md0.23
  29. 2022-09-06Investor Presentation2022-09-06_7211554_investor-presentation.md0.17
  30. 2022-08-11Trading Update And Notice OF Interim Results2022-08-11_7060335_trading-update-and-notice-of-interim-results.md0.23
  31. 2022-06-09Result OF Agm2022-06-09_6874997_result-of-agm.md0.07
  32. 2022-05-13Posting OF Annual Report And Notice OF Agm2022-05-13_6890547_posting-of-annual-report-and-notice-of-agm.md0.24
  33. 2022-02-17Trading Update2022-02-17_6851465_trading-update.md0.21
  34. 2021-11-26Result OF Placing2021-11-26_6641614_result-of-placing.md0.17
  35. 2021-11-26Proposed Placing2021-11-26_6640454_proposed-placing.md0.17
  36. 2021-09-16Interim Results2021-09-16_6865193_interim-results.md0.09

This research note was authored by a large language model after reading 32 regulatory filings published between 2021-09-16 and 2026-09-28. Each citation refers to a specific RNS announcement in the underlying data set. The note is an opinion, not advice. Do your own work before risking capital.